Comparative Pharmacology
Head-to-head clinical analysis: DENDRID versus LETERMOVIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DENDRID versus LETERMOVIR.
DENDRID vs LETERMOVIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dendrid (idoxuridine) is a pyrimidine nucleoside analog that inhibits viral DNA replication by incorporating into viral DNA and inhibiting thymidylate synthetase, thereby blocking DNA synthesis.
Letermovir is an antiviral agent that inhibits the human cytomegalovirus (CMV) terminase complex, specifically the pUL56 subunit, thereby preventing viral DNA processing and packaging.
1.5 mg/kg IV every 8 hours; typical adult dose 100 mg IV every 8 hours.
480 mg orally once daily (two 240 mg tablets).
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours in adults with normal renal function; prolonged in renal impairment
Clinical Note
moderateLetermovir + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Letermovir."
Clinical Note
moderateLetermovir + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Letermovir."
Clinical Note
moderateLetermovir + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Letermovir."
Clinical Note
moderateLetermovir + Dronedarone
The terminal elimination half-life is approximately 12 hours (range 10–18 hours) in healthy subjects, allowing once-daily dosing.
Primarily renal excretion; unchanged drug accounts for 70-90% of elimination; minor biliary/fecal excretion (<10%)
Letermovir is primarily eliminated via biliary/fecal excretion (approximately 93% of the dose recovered in feces, with <2% as unchanged drug) and renal excretion accounts for <7% (mostly as metabolites, <1% unchanged).
Category C
Category C
Antiviral
Antiviral
"The metabolism of Dronedarone can be decreased when combined with Letermovir."